CLINICAL TRIALS PROFILE FOR ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01990300 ↗ | Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus | Completed | Takeda | 2011-11-28 | The purpose of this survey is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride | |
| NCT03499704 ↗ | A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy | Recruiting | Celltrion Pharm, Inc. | Phase 4 | 2020-02-11 | The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 52. |
| NCT03499704 ↗ | A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy | Recruiting | Takeda | Phase 4 | 2020-02-11 | The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 52. |
| NCT03950505 ↗ | To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes | Recruiting | Yonsei University | Phase 4 | 2020-05-29 | This study was designed to evaluate the effect of Nesinaact on non-alcoholic steatohepatitis through magnetic resonance imaging (MRI)-based proton density-fat fraction (MRI-PDFF) and liver fibroscan in patients with type 2 diabetes. This is a prospective, open-label, single-arm, single-center clinical Study. After 24 weeks of Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment, the improvement of parameters estimated by MRI and liver fibroscan will be estimated. |
| NCT04470310 ↗ | Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination | Active, not recruiting | Seoul National University Hospital | Phase 4 | 2015-12-31 | - This trial is a three-armed, open label, random assignment trial. - The research subjects are patients who are first starting their treatment or patients who have failed with the metformin treatment and are changing their medication. They will be assigned to one of the following treatment groups: the glimepiride monotherapy treatment group, the alogliptin monotherapy treatment group, and the alogliptin - pioglitazone combination therapy treatment group - This trial is a prospective trial which will conduct surveys 6 times over the course of the 6 months in which each treatment group is administered drugs (Week -2, Baseline, Week 4, Week 12, Week 24, follow-up safety survey). - This trial is a multicenter clinical trial which will be conducted at more than 5 general hospital medical institutions in the vicinity of the capital. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Condition Name
Condition MeSH
Clinical Trial Locations for ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Clinical Trial Progress for ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
Sponsor Name
